benzofurans and cloridarol

Topics: Angina Pectoris; Benzofurans; Benzyl Alcohols; Clinical Trials as Topic; Dipyridamole; Drug Evaluation; Humans; Myocardial Infarction; Vasodilator Agents

Topics: Adult; Aged; Alcohols; Benzofurans; Clinical Trials as Topic; Coronary Disease; Evaluation Studies as Topic; Female; Glycogen; Heart; Humans; Male; Middle Aged; Myocardium; Pentaerythritol Tetranitrate

Accumulating evidence have shown a strong pathological correlation between cardiovascular disease (CVD) and Type II diabetes (T2D), both of which share many common risk factors (e.g., hyperglycemia, hypertension, hypercoagulability, and dyslipidemia) and mutually contribute to each other. Driven by such strong CVD-T2D correlation and marginal benefits from drug development for T2D, here we proposed to repurpose a CVD drug of cloridarol as human islet amyloid peptide (hIAPP) inhibitor against its abnormal misfolding and aggregation, which is considered as a common and critical pathological event in T2D. To this end, we investigated the inhibition activity of cloridarol on the aggregation and toxicity of hIAPP

Topics: Amyloidogenic Proteins; Benzofurans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Islet Amyloid Polypeptide; Pharmaceutical Preparations

Eighteen subjects, nine affected with type IIB and nine with type IV hyperlipemia, following since months a "prudent diet" received 750 mg/day of the compound/(2-benzofuryl) (p-chlorophenyl) carbinol/ for two 2-month periods. The results obtained were compared with those obtained following only dietary treatment. The pharmacological treatment significantly reduced the plasma levels of triglycerides and apoB.

Topics: Apolipoproteins; Apolipoproteins B; Benzofurans; Female; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Triglycerides

The efficacy of chloridarol (2-benzofuryl-p-chlorophenyl carbinol) as hypolipidemic agent was evaluated in rats and rabbits. In normolipidemic rats chloridarol, at doses ranging from 50 to 200 mg/kg/day, decreased plasma triglycerides without affecting cholesterolemia and fast- or norepinephrine-induced lipolysis. The drug proved effective in reducing fructose-induced hypertriglyceridemia and dietary hypercholesterolemia in rats; in the latter model chloridarol significantly raised both the HDL cholesterol and the HDL/VLDL + LDL cholesterol ratio. In hyperlipidemic rabbits the drug had no effect on plasma cholesterol, but it lowered triglyceridemia. The action of chloridarol on rat liver ultrastructure was also investigated. Treatment for one month induced peroxisome proliferation, less marked, however, than that elicited by clofibrate; after a prolonged chloridarol treatment (9 months), this effect had almost completely disappeared and the ultrastructure of the hepatocytes was close to that of controls.

Topics: Animals; Benzofurans; Clofibrate; Diet; Fatty Acids, Nonesterified; Hypolipidemic Agents; Lipolysis; Liver; Male; Nicotinic Acids; Norepinephrine; Rats; Rats, Inbred Strains

The therapeutical activity of a new oral drug with a coronaric and myocardiotrophic action of choice, 2-benzofuryl-p-chlorophenyl-carbinol (Menacor, Menarini) in 20 patients with chronic coronary insufficiency was studied by administering 750 mg/day for at least 20 days. General and gastroenteric tolerance was excellent, while good or fair therapeutic results were obtained in 16 cases (80%). It is felt that the drug can be usefully employed in the management of coronary insufficiency.

Topics: Aged; Benzofurans; Benzyl Alcohols; Coronary Disease; Female; Humans; Male; Middle Aged; Vasodilator Agents